1
|
Díez-Pascual AM. Carbon-Based Nanomaterials 4.0. Int J Mol Sci 2024; 25:3032. [PMID: 38474275 DOI: 10.3390/ijms25053032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2024] [Accepted: 03/01/2024] [Indexed: 03/14/2024] Open
Abstract
Research on carbon-based nanomaterials, such as carbon nanotubes and graphene and its derivatives, has experienced exponential development in recent years [...].
Collapse
Affiliation(s)
- Ana M Díez-Pascual
- Departamento de Química Analítica, Facultad de Ciencias, Química Física e Ingeniería Química, Universidad de Alcalá, Ctra, Madrid-Barcelona Km. 33.6, Alcalá de Henares, 28805 Madrid, Spain
| |
Collapse
|
2
|
Öztürk S, Demir M, Koçkaya EA, Karaaslan C, Süloğlu AK. Establishment of a 3D multicellular placental microtissues for investigating the effect of antidepressant vortioxetine. Reprod Toxicol 2024; 123:108519. [PMID: 38043629 DOI: 10.1016/j.reprotox.2023.108519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2023] [Revised: 10/23/2023] [Accepted: 11/30/2023] [Indexed: 12/05/2023]
Abstract
The placenta is a unique organ with an active metabolism and dynamically changing physiology throughout pregnancy. It is difficult to elucidate the structure of cell-cell and cell-extracellular matrix interactions of the placenta in in vivo studies due to interspecies differences and ethical constraints. In this study, human umbilical cord vein cells (HUVEC) and human placental choriocarcinoma cells (BeWo) were co-cultured for the first time to form spheroids (microtissues) on a three-dimensional (3D) Petri Dish® mold and compared with a traditional two-dimensional (2D) system. Vortioxetine is an antidepressant with a lack of literature on its use in pregnancy in established cultures, the toxicity of vortioxetine was studied to investigate the response of spheroids representing placental tissue. Spheroids were characterised by morphology and exposed to vortioxetine. Cell viability and barrier integrity were then measured. Intercellular junctions and the localisation of serotonin transporter (SERT) proteins were demonstrated by immunofluorescence (IF) staining in BeWo cells. Human chorionic gonadotropin (beta-hCG) hormone levels were also measured. In the 3D system, cell viability and hormone production were higher than in the 2D system. It was observed that the barrier structure was impaired, the structure of intracellular skeletal elements was altered and SERT expression decreased depending on vortioxetine exposure. These results demonstrate that the multicellular microtissue placenta model can be used to obtain results that more closely resemble in vivo toxicity studies of various xenobiotics than other 2D and mono-culture spheroid models in the literature. It also describes the use of 3D models for soft tissues other than the placenta.
Collapse
Affiliation(s)
- Selen Öztürk
- Hacettepe University, Faculty of Science, Department of Biology, Zoology Section, Beytepe Campus, Ankara, Türkiye
| | - Merve Demir
- Hacettepe University, Faculty of Science, Department of Biology, Zoology Section, Beytepe Campus, Ankara, Türkiye
| | - E Arzu Koçkaya
- Gazi University, The Higher Vocational School of Health Services, Gölbaşı Campus, Ankara, Türkiye
| | - Cagatay Karaaslan
- Hacettepe University, Faculty of Science, Department of Biology, Molecular Biology Section, Beytepe Campus, Ankara, Türkiye
| | - Aysun Kılıç Süloğlu
- Hacettepe University, Faculty of Science, Department of Biology, Zoology Section, Beytepe Campus, Ankara, Türkiye.
| |
Collapse
|
3
|
Use of Hierarchical Carbon Nanofibers Decorated with NiCo Nanoparticles for Highly Sensitive Vortioxetine Determination. Int J Mol Sci 2022; 23:ijms232314555. [PMID: 36498883 PMCID: PMC9739381 DOI: 10.3390/ijms232314555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2022] [Revised: 11/18/2022] [Accepted: 11/19/2022] [Indexed: 11/24/2022] Open
Abstract
A new voltammetry method for the highly sensitive antidepressant drug vortioxetine (VOR) is presented using glassy carbon electrodes modified with hierarchical carbon nanofibers with NiCo nanoparticles (eCNF/CNT/NiCo-GCE). The electrochemical behavior of VOR was investigated by cyclic voltammetry, which indicates that its oxidation is an adsorption-controlled process with the exchange of two electrons and one proton. The effects of various factors on the VOR peak, such as supporting electrolyte type, preconcentration time, and potential, or influence of interferents, were tested using the square wave voltammetry technique (SWV). The linear voltametric response for the analyte was obtained in the concentration range from 0.01·10-6 to 3.0·10-6 mol L-1 with the detection limit of 1.55·10-9 mol L-1 for a preconcentration time of 60 s. The proposed method was successfully applied for highly sensitive VOR determination in complex matrices such as tablets, urine, and plasma with good recovery parameter.
Collapse
|
4
|
Tian H, Hu Z, Xu J, Wang C. The molecular pathophysiology of depression and the new therapeutics. MedComm (Beijing) 2022; 3:e156. [PMID: 35875370 PMCID: PMC9301929 DOI: 10.1002/mco2.156] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Revised: 06/06/2022] [Accepted: 06/06/2022] [Indexed: 12/21/2022] Open
Abstract
Major depressive disorder (MDD) is a highly prevalent and disabling disorder. Despite the many hypotheses proposed to understand the molecular pathophysiology of depression, it is still unclear. Current treatments for depression are inadequate for many individuals, because of limited effectiveness, delayed efficacy (usually two weeks), and side effects. Consequently, novel drugs with increased speed of action and effectiveness are required. Ketamine has shown to have rapid, reliable, and long-lasting antidepressant effects in treatment-resistant MDD patients and represent a breakthrough therapy for patients with MDD; however, concerns regarding its efficacy, potential misuse, and side effects remain. In this review, we aimed to summarize molecular mechanisms and pharmacological treatments for depression. We focused on the fast antidepressant treatment and clarified the safety, tolerability, and efficacy of ketamine and its metabolites for the MDD treatment, along with a review of the potential pharmacological mechanisms, research challenges, and future clinical prospects.
Collapse
Affiliation(s)
- Haihua Tian
- Ningbo Key Laboratory of Behavioral Neuroscience Ningbo University School of Medicine Ningbo Zhejiang China.,Zhejiang Provincial Key Laboratory of Pathophysiology School of Medicine Ningbo University Ningbo Zhejiang China.,Department of Physiology and Pharmacology Ningbo University School of Medicine Ningbo Zhejiang China.,Department of Laboratory Medicine Ningbo Kangning Hospital Ningbo Zhejiang China
| | - Zhenyu Hu
- Department of Child Psychiatry Ningbo Kanning Hospital Ningbo Zhejiang China
| | - Jia Xu
- Ningbo Key Laboratory of Behavioral Neuroscience Ningbo University School of Medicine Ningbo Zhejiang China.,Zhejiang Provincial Key Laboratory of Pathophysiology School of Medicine Ningbo University Ningbo Zhejiang China.,Department of Physiology and Pharmacology Ningbo University School of Medicine Ningbo Zhejiang China
| | - Chuang Wang
- Ningbo Key Laboratory of Behavioral Neuroscience Ningbo University School of Medicine Ningbo Zhejiang China.,Zhejiang Provincial Key Laboratory of Pathophysiology School of Medicine Ningbo University Ningbo Zhejiang China.,Department of Physiology and Pharmacology Ningbo University School of Medicine Ningbo Zhejiang China
| |
Collapse
|
5
|
Yu Z, Bai R, Zhou J, Huang H, Zhao W, Huo X, Yang Y, Luan Z, Zhang B, Sun C, Ma X. Uncarialins J—M from
Uncaria rhynchophylla
and Their Anti‐depression Mechanism in Unpredictable Chronic Mild
Stress‐Induced
Mice
via
Activating
5‐HT
1A
Receptor. CHINESE J CHEM 2021. [DOI: 10.1002/cjoc.202000652] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- Zhen‐Long Yu
- Dalian Key Laboratory of Metabolic Target Characterization and Traditional Chinese Medicine Intervention, National & Local Joint Engineering Research Center for Drug Development of Neurodegenerative Disease, College of Pharmacy, College (Institute) of Integrative Medicine, Dalian Medical University Dalian Liaoning 116044 China
| | - Rong Bai
- Department of Pharmacy, Shanghai East Hospital, Tongji University Shanghai 200120 China
| | - Jun‐Jun Zhou
- Dalian Key Laboratory of Metabolic Target Characterization and Traditional Chinese Medicine Intervention, National & Local Joint Engineering Research Center for Drug Development of Neurodegenerative Disease, College of Pharmacy, College (Institute) of Integrative Medicine, Dalian Medical University Dalian Liaoning 116044 China
| | - Hui‐Lian Huang
- Laboratory of Modern Preparation of Traditional Chinese Medicine, Ministry of Education, Jiangxi University of Traditional Chinese Medicine, Nanchang Jiangxi 330103 China
| | - Wen‐Yu Zhao
- Dalian Key Laboratory of Metabolic Target Characterization and Traditional Chinese Medicine Intervention, National & Local Joint Engineering Research Center for Drug Development of Neurodegenerative Disease, College of Pharmacy, College (Institute) of Integrative Medicine, Dalian Medical University Dalian Liaoning 116044 China
| | - Xiao‐Kui Huo
- Dalian Key Laboratory of Metabolic Target Characterization and Traditional Chinese Medicine Intervention, National & Local Joint Engineering Research Center for Drug Development of Neurodegenerative Disease, College of Pharmacy, College (Institute) of Integrative Medicine, Dalian Medical University Dalian Liaoning 116044 China
| | - Ya‐Hui Yang
- Dalian Key Laboratory of Metabolic Target Characterization and Traditional Chinese Medicine Intervention, National & Local Joint Engineering Research Center for Drug Development of Neurodegenerative Disease, College of Pharmacy, College (Institute) of Integrative Medicine, Dalian Medical University Dalian Liaoning 116044 China
| | - Zhi‐Lin Luan
- Dalian Key Laboratory of Metabolic Target Characterization and Traditional Chinese Medicine Intervention, National & Local Joint Engineering Research Center for Drug Development of Neurodegenerative Disease, College of Pharmacy, College (Institute) of Integrative Medicine, Dalian Medical University Dalian Liaoning 116044 China
| | - Bao‐Jing Zhang
- Dalian Key Laboratory of Metabolic Target Characterization and Traditional Chinese Medicine Intervention, National & Local Joint Engineering Research Center for Drug Development of Neurodegenerative Disease, College of Pharmacy, College (Institute) of Integrative Medicine, Dalian Medical University Dalian Liaoning 116044 China
| | - Cheng‐Peng Sun
- Dalian Key Laboratory of Metabolic Target Characterization and Traditional Chinese Medicine Intervention, National & Local Joint Engineering Research Center for Drug Development of Neurodegenerative Disease, College of Pharmacy, College (Institute) of Integrative Medicine, Dalian Medical University Dalian Liaoning 116044 China
| | - Xiao‐Chi Ma
- Dalian Key Laboratory of Metabolic Target Characterization and Traditional Chinese Medicine Intervention, National & Local Joint Engineering Research Center for Drug Development of Neurodegenerative Disease, College of Pharmacy, College (Institute) of Integrative Medicine, Dalian Medical University Dalian Liaoning 116044 China
| |
Collapse
|
6
|
Qiao YL, Zhou JJ, Liang JH, Deng XP, Zhang ZJ, Huang HL, Li S, Dai SF, Liu CQ, Luan ZL, Yu ZL, Sun CP, Ma XC. Uncaria rhynchophylla ameliorates unpredictable chronic mild stress-induced depression in mice via activating 5-HT 1A receptor: Insights from transcriptomics. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2021; 81:153436. [PMID: 33360346 DOI: 10.1016/j.phymed.2020.153436] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/08/2020] [Revised: 11/29/2020] [Accepted: 12/03/2020] [Indexed: 06/12/2023]
Abstract
BACKGROUND Depression is a pervasive or persistent mental disorder that causes mood, cognitive and memory deficits. Uncaria rhynchophylla has been widely used to treat central nervous system diseases for a long history, although its efficacy and potential mechanism are still uncertain. PURPOSE The present study aimed to investigate anti-depression effect and potential mechanism of U. rhynchophylla extract (URE). STUDY DESIGN AND METHODS A mouse depression model was established using unpredictable chronic mild stress (UCMS). Effects of URE on depression-like behaviours, neurotransmitters, and neuroendocrine hormones were investigated in UCMS-induced mice. The potential target of URE was analyzed by transcriptomics and bioinformatics methods and validated by RT-PCR and Western blot. The agonistic effect on 5-HT1A receptor was assayed by dual-luciferase reporter system. RESULTS URE ameliorated depression-like behaviours, and modulated levels of neurotransmitters and neuroendocrine hormones, including 5-hydroxytryptamine (5-HT), 5-hydroxyindole acetic acid (5-HIAA), dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), corticosterone (CORT), corticotropin-releasing hormone (CRH), and adrenocorticotropic hormone (ACTH), in UCMS-induced mice. Transcriptomics and bioinformatics results indicated that URE could regulate glutamatergic, cholinergic, serotonergic, and GABAergic systems, especially neuroactive ligand-receptor and cAMP signaling pathways, revealing that Htr1a encoding 5-HT1A receptor was a potential target of URE. The expression levels of downstream proteins of 5-HT1A signaling pathway 5-HT1A, CREB, BDNF, and PKA were increased in UCMS-induced mice after URE administration, and URE also displayed an agonistic effect against 5-HT1A receptor with an EC50 value of 17.42 μg/ml. CONCLUSION U. rhynchophylla ameliorated depression-like behaviours in UCMS-induced mice through activating 5-HT1A receptor.
Collapse
Affiliation(s)
- Yan-Ling Qiao
- Dalian Key Laboratory of Metabolic Target Characterization and Traditional Chinese Medicine, College of Pharmacy, College of Integrative Medicine, Department of Neurosurgery, The First and Second Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China
| | - Jun-Jun Zhou
- Dalian Key Laboratory of Metabolic Target Characterization and Traditional Chinese Medicine, College of Pharmacy, College of Integrative Medicine, Department of Neurosurgery, The First and Second Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China
| | - Jia-Hao Liang
- Dalian Key Laboratory of Metabolic Target Characterization and Traditional Chinese Medicine, College of Pharmacy, College of Integrative Medicine, Department of Neurosurgery, The First and Second Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China
| | - Xiao-Peng Deng
- Dalian Key Laboratory of Metabolic Target Characterization and Traditional Chinese Medicine, College of Pharmacy, College of Integrative Medicine, Department of Neurosurgery, The First and Second Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China
| | - Zhan-Jun Zhang
- State Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University, Beijing, China
| | - Hui-Lian Huang
- Laboratory of Modern Preparation of Traditional Chinese Medicine, Ministry of Education, Jiangxi University of Traditional Chinese Medicine, Nanchang, China
| | - Song Li
- Dalian Key Laboratory of Metabolic Target Characterization and Traditional Chinese Medicine, College of Pharmacy, College of Integrative Medicine, Department of Neurosurgery, The First and Second Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China
| | - Shu-Fang Dai
- Dalian Key Laboratory of Metabolic Target Characterization and Traditional Chinese Medicine, College of Pharmacy, College of Integrative Medicine, Department of Neurosurgery, The First and Second Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China
| | - Chun-Qing Liu
- Dalian Key Laboratory of Metabolic Target Characterization and Traditional Chinese Medicine, College of Pharmacy, College of Integrative Medicine, Department of Neurosurgery, The First and Second Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China
| | - Zhi-Lin Luan
- Dalian Key Laboratory of Metabolic Target Characterization and Traditional Chinese Medicine, College of Pharmacy, College of Integrative Medicine, Department of Neurosurgery, The First and Second Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China
| | - Zhen-Long Yu
- Dalian Key Laboratory of Metabolic Target Characterization and Traditional Chinese Medicine, College of Pharmacy, College of Integrative Medicine, Department of Neurosurgery, The First and Second Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China
| | - Cheng-Peng Sun
- Dalian Key Laboratory of Metabolic Target Characterization and Traditional Chinese Medicine, College of Pharmacy, College of Integrative Medicine, Department of Neurosurgery, The First and Second Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China.
| | - Xiao-Chi Ma
- Dalian Key Laboratory of Metabolic Target Characterization and Traditional Chinese Medicine, College of Pharmacy, College of Integrative Medicine, Department of Neurosurgery, The First and Second Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China; State Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University, Beijing, China.
| |
Collapse
|
7
|
Duan L, Gao Y, Shao X, Tian C, Fu C, Zhu G. Research on the Development of Theme Trends and Changes of Knowledge Structures of Drug Therapy Studies on Major Depressive Disorder Since the 21 st Century: A Bibliometric Analysis. Front Psychiatry 2020; 11:647. [PMID: 32754061 PMCID: PMC7367417 DOI: 10.3389/fpsyt.2020.00647] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2020] [Accepted: 06/22/2020] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Antidepressant treatment is one of the most effective ways of relieving or curing depressive symptoms in patients with major depressive disorder (MDD). Although many studies have explored the efficacy, tolerability, adverse reactions, and functional mechanism of the disease, there has been no systematic evaluation of the relevant results in this field. AIM This paper aims to analyze the theme trends and knowledge structure of drug therapy studies on MDD since the 21st century by employing bibliometric analysis. METHODS Literature published in PubMed and related to drug therapy studies on MDD were retrieved between 2001 and 2018 in 6-year increments. After extracting major Medical Subject Headings (MeSH) terms/MeSH subheadings, bi-clustering analysis, social network analysis, and strategic diagrams were employed to complete bibliometric analysis. RESULTS Overall, 1,577, 2,680, 2,848 relevant research articles were retrieved for the periods during 2001-2006, 2007-2012, and 2013-2018, respectively. In line with strategic diagrams, the main undeveloped and peripheral theme clusters during 2001-2006 were functional mechanisms of antidepressants in pathophysiology, neuroendocrinology and neural biochemistry. These themes were replaced during 2007-2012 by clinical efficacy and influencing factors of antidepressants with or without psychotherapy, mechanisms of adverse reactions of antidepressants, and predictive studies of clinical therapeutic effects of antidepressants based on brain imaging. During 2013-2018 application and evaluation of new antidepressant agents, early identification and prevention of suicide of patients with MDD, as well as genetic- or bio-markers affecting the response and efficacy of antidepressants were the primary themes. Based on social network analyses, emerging hotspots, such as antidepressive agents, second-generation/adverse effects, depressive disorder, major/metabolism, psychotherapy/methods, and brain/drug effects could be identified during 2007-2012 and 2013-2018. CONCLUSIONS These undeveloped theme clusters and emerging hotspots can be helpful for researchers to clarify the current status of their respective fields and future trends, and to generate novel ideas that may launch new research directions.
Collapse
Affiliation(s)
- Li Duan
- Department of Psychiatry, The First Affiliated Hospital of China Medical University, Shenyang, China.,School of Nursing, Chengde Medical University, Chengde, China
| | - Yunfeng Gao
- Department of Hand and Foot Surgery, The Affiliated Hospital of Chengde Medical University, Chengde, China
| | - Xiaojun Shao
- Department of Psychiatry, The First Affiliated Hospital of China Medical University, Shenyang, China
| | - ChunSheng Tian
- Department of Psychiatry, The First Affiliated Hospital of China Medical University, Shenyang, China
| | - Chunfeng Fu
- Department of Psychiatry, The First Affiliated Hospital of China Medical University, Shenyang, China
| | - Gang Zhu
- Department of Psychiatry, The First Affiliated Hospital of China Medical University, Shenyang, China.,Central Laboratory, The First Affiliated Hospital of China Medical University, Shenyang, China
| |
Collapse
|
8
|
Perini G, Cotta Ramusino M, Sinforiani E, Bernini S, Petrachi R, Costa A. Cognitive impairment in depression: recent advances and novel treatments. Neuropsychiatr Dis Treat 2019; 15:1249-1258. [PMID: 31190831 PMCID: PMC6520478 DOI: 10.2147/ndt.s199746] [Citation(s) in RCA: 177] [Impact Index Per Article: 35.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/28/2018] [Accepted: 03/14/2019] [Indexed: 12/14/2022] Open
Abstract
In the past, little or no attention was paid to cognitive disorders associated with depression (a condition sometimes termed pseudodementia). However, recent years have seen a growing interest in these changes, not only because of their high frequency in acute-stage depression, but also because they have been found to persist, as residual symptoms (in addition to affective and psychomotor ones), in many patients who respond well to antidepressant treatment. These cognitive symptoms seem to impact significantly not only on patients' functioning and quality of life, but also on the risk of recurrence of depression. Therefore, over the past decade, pharmacological research in this field has focused on the development of new agents able to counteract not only depressive symptoms, but also cognitive and functional ones. In this context, novel antidepressants with multimodal activity have emerged. This review considers the different issues, in terms of disease evolution, raised by the presence of cognitive disorders associated with depression and considers, particularly from the neurologist's perspective, the ways in which the clinical approach to cognitive symptoms, and their interpretation to diagnostic and therapeutic ends, have changed in recent years. Finally, after outlining the pharmacodynamics and pharmacokinetics of the first multimodal antidepressant, vortioxetine, it reports the main results obtained with the drug in depressed patients, also in consideration of the ever-increasing evidence on its different mechanisms of action in animal models.
Collapse
Affiliation(s)
- Giulia Perini
- Center of Cognitive and Behavioral Disorders, IRCCS Fondazione Mondino, National Institute of Neurology, Pavia, Italy.,Department of Brain and Behavior, University of Pavia, Pavia, Italy
| | - Matteo Cotta Ramusino
- Center of Cognitive and Behavioral Disorders, IRCCS Fondazione Mondino, National Institute of Neurology, Pavia, Italy.,Department of Brain and Behavior, University of Pavia, Pavia, Italy
| | - Elena Sinforiani
- Center of Cognitive and Behavioral Disorders, IRCCS Fondazione Mondino, National Institute of Neurology, Pavia, Italy
| | - Sara Bernini
- Center of Cognitive and Behavioral Disorders, IRCCS Fondazione Mondino, National Institute of Neurology, Pavia, Italy
| | - Roberto Petrachi
- Unit of Mood Disorders, Psychiatry Service, ASST, Acqui Terme, Alessandria, Italy
| | - Alfredo Costa
- Center of Cognitive and Behavioral Disorders, IRCCS Fondazione Mondino, National Institute of Neurology, Pavia, Italy.,Department of Brain and Behavior, University of Pavia, Pavia, Italy
| |
Collapse
|
9
|
Lax NC, Parker SAJ, Hilton EJ, Seliman Y, Tidgewell KJ, Kolber BJ. Cyanobacterial extract with serotonin receptor subtype 7 (5-HT 7 R) affinity modulates depression and anxiety-like behavior in mice. Synapse 2018; 72:e22059. [PMID: 29992647 DOI: 10.1002/syn.22059] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2018] [Revised: 06/15/2018] [Accepted: 07/06/2018] [Indexed: 12/20/2022]
Abstract
Marine cyanobacteria represent a unique source in the field of drug discovery due to the secondary metabolites they produce and the structural similarity these compounds have to endogenous mammalian receptor ligands. A series of cyanobacteria were subjected to extraction, fractionation by column chromatography and screened for affinity against CNS targets with a focus on serotonin receptors (5-HTRs). Out of 276 fractions screened, 21% had activity at 5-HTRs and/or the 5-HT transporter (SERT). One sample, a cyanobacterium identified by 16S rRNA sequencing as Leptolyngbya from Las Perlas archipelago in Panama, contained a fraction with noted affinity for the 5-HT7 receptor (5-HT7 R). This fraction (DUQ0002I) was screened via intracerebroventricular (ICV) injections in mice using depression and anxiety assays including the forced swim, tail suspension, elevated zero maze, and light-dark preference tests. DUQ0002I decreased depression and anxiety-like behaviors in males and did not have effects in 5-HT7 R knockout or female mice. Administration of DUQ0002I to the CA1 of the hippocampus induced antidepression-like, but not anxiolytic-like behaviors. Testing of further purified materials showed no behavioral effects, leading us to hypothesize that the behavioral effects are likely caused by a synergistic effect between multiple compounds in the fraction. Finally, DUQ0002I was used in a model of neuropathic pain with comorbid depression (spared nerve injury-SNI). DUQ0002I had a similar antidepressant effect in animals with SNI, suggesting a role for the 5-HT7 R in the development of comorbid pain and depression. These results demonstrate the potential that cyanobacterial metabolites have in the field of neuropharmacognosy.
Collapse
Affiliation(s)
- Neil C Lax
- Department of Biological Sciences, Duquesne University, Pittsburgh, Pennsylvania.,Chronic Pain Research Consortium, Duquesne University, Pittsburgh, Pennsylvania
| | - Stacy-Ann J Parker
- Mylan School of Pharmacy, Duquesne University, Pittsburgh, Pennsylvania.,Chronic Pain Research Consortium, Duquesne University, Pittsburgh, Pennsylvania
| | - Edward J Hilton
- Department of Biological Sciences, Duquesne University, Pittsburgh, Pennsylvania.,Chronic Pain Research Consortium, Duquesne University, Pittsburgh, Pennsylvania
| | - Youstina Seliman
- Department of Biological Sciences, Duquesne University, Pittsburgh, Pennsylvania.,Chronic Pain Research Consortium, Duquesne University, Pittsburgh, Pennsylvania
| | - Kevin J Tidgewell
- Mylan School of Pharmacy, Duquesne University, Pittsburgh, Pennsylvania.,Chronic Pain Research Consortium, Duquesne University, Pittsburgh, Pennsylvania
| | - Benedict J Kolber
- Department of Biological Sciences, Duquesne University, Pittsburgh, Pennsylvania.,Chronic Pain Research Consortium, Duquesne University, Pittsburgh, Pennsylvania
| |
Collapse
|
10
|
Kennedy SH, Grouin JM, Cadour S, Robert V, Picarel-Blanchot F. Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder. Hum Psychopharmacol 2018; 33. [PMID: 29327372 DOI: 10.1002/hup.2646] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/28/2017] [Revised: 11/02/2017] [Accepted: 11/21/2017] [Indexed: 11/08/2022]
Abstract
Agomelatine and vortioxetine are antidepressants with different mechanisms of action compared to other pharmaceutical treatment options. The objective of this present analysis is to determine the relative efficacy and acceptability of agomelatine (25-50 mg) compared to vortioxetine (10-15-20 mg) in adult patients with major depressive disorder. We performed an adjusted indirect comparison using placebo as a common control. The main outcomes were efficacy (response to treatment by Montgomery-Åsberg depression rating scale/Hamilton Rating Scale for Depression) and acceptability (withdrawal rate for any reason or due to adverse events). 10 agomelatine and 11 vortioxetine studies were included in the analysis. For efficacy, no difference was shown between agomelatine and vortioxetine (E[95% CI] = -0.03 [-0.12;0.05]). For acceptability, no significant difference was found between both antidepressants. These findings substantiate current understanding that most antidepressants are of similar average efficacy and tolerability. Such equivalent therapeutic benefit of both compounds, measured by a quantitative clinical research approach, has to be discussed with the knowledge of a qualitative estimation in routine practice.
Collapse
Affiliation(s)
- Sidney H Kennedy
- University of Toronto, St. Michael's Hospital, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada
| | | | - Stéphanie Cadour
- Biostatistics Department and Neuropsychiatry Center for Therapeutic Innovation, Institut de Recherches Internationales Servier (IRIS), Suresnes, France
| | - Véronique Robert
- Biostatistics Department and Neuropsychiatry Center for Therapeutic Innovation, Institut de Recherches Internationales Servier (IRIS), Suresnes, France
| | - Françoise Picarel-Blanchot
- Biostatistics Department and Neuropsychiatry Center for Therapeutic Innovation, Institut de Recherches Internationales Servier (IRIS), Suresnes, France
| |
Collapse
|
11
|
Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder. Mol Psychiatry 2015; 20:1142-50. [PMID: 26148812 DOI: 10.1038/mp.2015.92] [Citation(s) in RCA: 85] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/22/2015] [Revised: 03/24/2015] [Accepted: 06/01/2015] [Indexed: 02/07/2023]
Abstract
Depression is a devastating disorder that places a significant burden on both the individual and society. As such, the discovery of novel therapeutics and innovative treatments--especially for treatment-resistant depression (TRD)--are essential. Research into antidepressant therapies for TRD has evolved from explorations of antidepressants with primary mechanisms of action on the monoaminergic neurotransmitter system to augmentation agents with primary mechanisms both within and outside of the serotonin/norepinephrine system. Now the field of antidepressant research has changed trajectories yet again; this time, compounds with primary mechanisms of action on the glutamatergic, cholinergic and opioid systems are in the forefront of antidepressant exploration. In this review, we will discuss the most recent research surrounding these novel compounds. In addition, we will discuss novel device-based therapeutics, with a particular focus on transcranial magnetic stimulation. In many cases of antidepressant drug discovery, the role of serendipity coupled with meticulous clinical observation in drug development in medicine was crucial. Moving forward, we must look toward the combination of innovation plus improvements on the remarkable discoveries thus far to advance the field of antidepressant research.
Collapse
|
12
|
Kelliny M, Croarkin PE, Moore KM, Bobo WV. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. Ther Clin Risk Manag 2015; 11:1193-212. [PMID: 26316764 PMCID: PMC4542474 DOI: 10.2147/tcrm.s55313] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
This article reviews the pharmacological profile and available efficacy and tolerability/safety data for vortioxetine, one of the most recent antidepressant drugs to be approved in the USA for the treatment of major depressive disorder (MDD) in adults. The efficacy of vortioxetine for treating MDD in adults is supported by eight positive short-term (6- to 12-weeks) randomized, placebo-controlled trials, and one positive randomized, double-blind, 52-week relapse prevention trial. Based on pooled data from short-term randomized trials and from longer-term studies, vortioxetine appears to be well tolerated and to have a low incidence of adverse effects on sexual functioning. Vortioxetine also appears to be effective for treating symptoms of MDD in the elderly based on the results of one randomized trial for which recruitment was focused on this specific population. Nevertheless, effectiveness studies that directly compare the clinical effects of vortioxetine with other established antidepressant drugs are lacking, and there is no evidence as yet that vortioxetine is more clinically effective than other types of antidepressants. Some preliminary suggestions concerning the place of vortioxetine among the broad range of pharmacological treatments for adults with MDD are provided.
Collapse
Affiliation(s)
- Marc Kelliny
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA
| | - Paul E Croarkin
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA
| | - Katherine M Moore
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA
| | - William V Bobo
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA
| |
Collapse
|
13
|
Keks NA, Hope J, Culhane C. Vortioxetine: A multimodal antidepressant or another selective serotonin reuptake inhibitor? Australas Psychiatry 2015; 23:210-3. [PMID: 25907797 DOI: 10.1177/1039856215581297] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
OBJECTIVE The treatment of depressive disorders remains unsatisfactory for many patients with regard to efficacy and tolerability. Vortioxetine has been registered by regulatory authorities for the treatment of major depressive disorder. This paper aims to provide clinicians with a brief overview of vortioxetine and its place in treatment. CONCLUSIONS Vortioxetine is a serotonin reuptake inhibitor with additional serotonergic receptor effects of uncertain significance; hence, its classification as 'multimodal'. The half-life is about 2.75 days and steady state requires about 14 days. Metabolism is hepatic and involves cytochromes 2D6 and 3A4/5. Antidepressant efficacy in major depressive disorder has been established in registration studies, but the effectiveness of vortioxetine in 'real world' patients and in comparison to other antidepressants needs further investigation. The recommended dose range is 5-20 mg. Nausea, constipation and vomiting are the most common side effects. Sexual dysfunction may occur at higher doses but there appears to be low risk of weight gain and sedation. There is still much to learn about this drug, particularly whether it has unique characteristics in comparison to existing antidepressants. At present, vortioxetine can be considered as an antidepressant option in patients with established major depressive disorder who have not responded adequately to other antidepressants.
Collapse
Affiliation(s)
- Nicholas A Keks
- Monash University and Centre of Mental Health Education and Research at Delmont Private Hospital, Melbourne, VIC, Australia
| | - Judy Hope
- Monash University, Eastern Health and Centre of Mental Health Education and Research at Delmont Private Hospital, Melbourne, VIC, Australia
| | - Christine Culhane
- Psychotropic Drug Advisory Service at the Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia
| |
Collapse
|
14
|
Al-Sukhni M, Maruschak NA, McIntyre RS. Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin Drug Saf 2015; 14:1291-304. [PMID: 26022537 DOI: 10.1517/14740338.2015.1046836] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
INTRODUCTION Vortioxetine is a pharmacodynamically novel antidepressant that exerts effects on various neurotransmitters including serotonin, noradrenaline, dopamine, glutamate, histamine and acetylcholine. Its efficacy in the symptomatic management of major depressive disorder (MDD) has been established in several short- and long-term trials. Vortioxetine has also demonstrated independent pro-cognitive effects in adults with MDD. AREAS COVERED This report provides a concise review of the pharmacology, efficacy and safety of vortioxetine as they pertain to cognition. EXPERT OPINION The significant impact of cognitive dysfunction in MDD has achieved increased consideration among researchers over the past decade. Vortioxetine is the first antidepressant agent to demonstrate meaningful clinical efficacy in the improvement of cognition in adults with MDD, independent of improvement in affective symptomatology. These results provide the impetus for further study into the potential pro-cognitive effects of vortioxetine in other conditions wherein cognitive dysfunction is prominent.
Collapse
Affiliation(s)
- Mayce Al-Sukhni
- General Psychiatry and Acute Care Units, Centre for Addiction and Mental Health , 250 College Street, Toronto, ON M5T 1R8 , Canada
| | | | | |
Collapse
|
15
|
Hillhouse TM, Porter JH. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol 2015; 23:1-21. [PMID: 25643025 PMCID: PMC4428540 DOI: 10.1037/a0038550] [Citation(s) in RCA: 280] [Impact Index Per Article: 31.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Major depressive disorder (MDD) is a chronic, recurring, and debilitating mental illness that is the most common mood disorder in the United States. It has been almost 50 years since the monoamine hypothesis of depression was articulated, and just over 50 years since the first pharmacological treatment for MDD was discovered. Several monoamine-based pharmacological drug classes have been developed and approved for the treatment of MDD; however, remission rates are low (often less than 60%) and there is a delayed onset before remission of depressive symptoms is achieved. As a result of a "proof-of-concept" study in 2000 with the noncompetitive NMDA antagonist ketamine, a number of studies have examined the glutamatergic systems as viable targets for the treatment of MDD. This review will provide a brief history on the development of clinically available antidepressant drugs, and then review the possible role of glutamatergic systems in the pathophysiology of MDD. Specifically, the glutamatergic review will focus on the N-methyl-D-aspartate (NMDA) receptor and the efficacy of drugs that target the NMDA receptor for the treatment of MDD. The noncompetitive NMDA receptor antagonist ketamine, which has consistently produced rapid and sustained antidepressant effects in MDD patients in a number of clinical studies, has shown the most promise as a novel glutamatergic-based treatment for MDD. However, compounds that target other glutamatergic mechanisms, such as GLYX-13 (a glycine-site partial agonist at NMDA receptors) appear promising in early clinical trials. Thus, the clinical findings to date are encouraging and support the continued search for and the development of novel compounds that target glutamatergic mechanisms.
Collapse
Affiliation(s)
- Todd M. Hillhouse
- the Department of Psychology at Virginia Commonwealth University at the time this review was written and is now at the University of Michigan in the Department of Pharmacology
| | - Joseph H. Porter
- the Department of Psychology at Virginia Commonwealth University
| |
Collapse
|